For patients who are fit and have a performance status high enough to continue therapy, [trabectedin] is a reasonable choice.
Kathleen Moore, MD
Session moderator Kathleen Moore, MD, Associate Professor of Obstetrics and Gynecology at the University of Oklahoma College of Medicine, Oklahoma City, said that while the response rates are “not incredibly high,” trabectedin offers another line of therapy where there previously was none.
“I think it’s a really important study,” said Dr. Moore. “In the past, there have been very few effective therapies for patients with soft-tissue sarcomas. After patients progressed through dacarbazine, ifosfamide, and doxorubicin, there was nothing else to offer them.”
With these data, said Dr. Moore, trabectedin offers clinicians another line of therapy with a reasonable response rate. “For patients who are fit and have a performance status high enough to continue therapy, it’s a reasonable choice,” she continued. “Patients do get benefit and prolonged progression-free survival, and it’s something that you can use in the second or third line following doxorubicin therapy. I think it has tremendous implications.” ■
Disclosure: Dr. Moore is on the advisory boards for Advaxis, Amgen, AstraZeneca, Genentech/Roche, VBL Therapeutics, and Merrimack.
In women with uterine leiomyosarcoma, trabectedin (Yondelis), a novel cytotoxic agent, significantly improved progression-free survival, compared with dacarbazine (4.2 vs 1.5 months, hazard ratio [HR] = 0.55, P < .001). According to the study’s authors, a lack of cumulative toxicity allows...